KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Research & Development (2018 - 2025)

Vir Biotechnology's Research & Development history spans 8 years, with the latest figure at $88.3 million for Q4 2025.

  • For Q4 2025, Research & Development fell 16.72% year-over-year to $88.3 million; the TTM value through Dec 2025 reached $456.0 million, down 9.98%, while the annual FY2025 figure was $456.0 million, 9.98% down from the prior year.
  • Research & Development for Q4 2025 was $88.3 million at Vir Biotechnology, down from $151.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $195.2 million in Q3 2024 and bottomed at $86.1 million in Q2 2021.
  • The 5-year median for Research & Development is $114.6 million (2022), against an average of $123.6 million.
  • The largest annual shift saw Research & Development surged 107.56% in 2021 before it crashed 38.84% in 2024.
  • A 5-year view of Research & Development shows it stood at $128.3 million in 2021, then grew by 20.91% to $155.2 million in 2022, then dropped by 29.78% to $109.0 million in 2023, then dropped by 2.65% to $106.1 million in 2024, then decreased by 16.72% to $88.3 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Research & Development are $88.3 million (Q4 2025), $151.5 million (Q3 2025), and $97.5 million (Q2 2025).